UCB (OTCMKTS:UCBJF) Shares Gap Up – Time to Buy?

UCB SA (OTCMKTS:UCBJF) shares gapped up prior to trading on Friday . The stock had previously closed at $231.75, but opened at $250.43. UCB shares last traded at $246.3175, with a volume of 165 shares changing hands.

Wall Street Analyst Weigh In

Several research firms recently commented on UCBJF. Piper Sandler restated a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.

UCB Price Performance

The stock’s fifty day simple moving average is $269.27 and its 200-day simple moving average is $287.85. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.